These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21208874)

  • 1. Can we IMPROVE bleeding risk assessment for acutely ill, hospitalized medical patients?
    Tay KH; Lip GY; Lane DA
    Chest; 2011 Jan; 139(1):10-3. PubMed ID: 21208874
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.
    Decousus H; Tapson VF; Bergmann JF; Chong BH; Froehlich JB; Kakkar AK; Merli GJ; Monreal M; Nakamura M; Pavanello R; Pini M; Piovella F; Spencer FA; Spyropoulos AC; Turpie AG; Zotz RB; Fitzgerald G; Anderson FA;
    Chest; 2011 Jan; 139(1):69-79. PubMed ID: 20453069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hemorrhagic risk: how to evaluate it.
    Di Fusco SA; Colivicchi F; Santini M
    Pacing Clin Electrophysiol; 2013 Oct; 36(10):1191-7. PubMed ID: 23663153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.
    Ludlam CA; Bennett B; Fox KA; Lowe GD; Reid AW
    Blood Coagul Fibrinolysis; 1995 May; 6(3):273-85. PubMed ID: 7654941
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bleeding during anti-vitamin K treatment. Incidence, risk factors and comparison with the new oral anticoagulants].
    Korin J
    Medicina (B Aires); 2012; 72(5):419-24. PubMed ID: 23089119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.
    Bergmann JF; Cohen AT; Tapson VF; Goldhaber SZ; Kakkar AK; Deslandes B; Huang W; Anderson FA;
    Thromb Haemost; 2010 Apr; 103(4):736-48. PubMed ID: 20135072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Factor XI activity as a promising antithrombotic strategy.
    Chen Z; Seiffert D; Hawes B
    Drug Discov Today; 2014 Sep; 19(9):1435-9. PubMed ID: 24794465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system.
    Rosenberg D; Eichorn A; Alarcon M; McCullagh L; McGinn T; Spyropoulos AC
    J Am Heart Assoc; 2014 Nov; 3(6):e001152. PubMed ID: 25404191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?
    Pamukcu B; Lane DA; Lip GY
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1703-10. PubMed ID: 21108552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing bleeding risk in acute coronary syndromes.
    Erdem G; Flather M
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):4-6. PubMed ID: 22056593
    [No Abstract]   [Full Text] [Related]  

  • 11. Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency.
    Cook DJ; Douketis J; Arnold D; Crowther MA
    Curr Opin Pulm Med; 2009 Sep; 15(5):455-62. PubMed ID: 19617833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™.
    Mathews R; Peterson ED; Chen AY; Wang TY; Chin CT; Fonarow GC; Cannon CP; Rumsfeld JS; Roe MT; Alexander KP
    Am J Cardiol; 2011 Apr; 107(8):1136-43. PubMed ID: 21324428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study.
    Silvestri F; Pasca S; Labombarda A; Barbi A; Desideri M; Guidi P; Rogato A; Zaramella M; Bergamo M; Ageno W; Barillari G
    Minerva Med; 2014 Jun; 105(3):221-8. PubMed ID: 24988087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticoagulant therapy in venous thromboembolism].
    Beyer J; Schellong S
    Herz; 2008 Feb; 33(1):52-8. PubMed ID: 18273578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological issues affecting estimates of bleeding risks and consequences after venous thromboembolism.
    Glynn RJ
    Thromb Haemost; 2009 May; 101(5):797-8. PubMed ID: 19404527
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient selection for thromboprophylaxis in medical inpatients.
    Bozzato S; Squizzato A; Donadini MP; Guasti L; Dentali F; Ageno W
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1639-47. PubMed ID: 24215194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response.
    Whitlock R; Danter M
    Chest; 2013 May; 143(5):1514. PubMed ID: 23648925
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary venous thromboembolism prophylaxis in ambulatory cancer patients.
    Aikens GB; Rivey MP; Hansen CJ
    Ann Pharmacother; 2013 Feb; 47(2):198-209. PubMed ID: 23386067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic guidelines in diabetes.
    Sharma GV; Mukerjee DK; Sasahara AA
    Geriatrics; 1982 Apr; 37(4):38-42, 46. PubMed ID: 7060947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The antithrombotic-treated patient].
    Nielsen JD; Rasmussen HM; Husted SE
    Ugeskr Laeger; 2006 Dec; 168(49):4296-9. PubMed ID: 17164056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.